Theriva Biologics (TOVX) Other Non-Current Assets (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Other Non-Current Assets of $81000.0 for Q1 2026, up 5.19% year-over-year from $77000.0 in Q1 2025, and up 76.09% quarter-over-quarter from $46000.0 in Q4 2025.
Theriva Biologics (TOVX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Other Non-Current Assets for 17 consecutive years, with $81000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 5.19% year-over-year to $81000.0; the TTM figure through Mar 2026 stood at $81000.0 (up 5.19% YoY), while the FY2025 annual figure was $46000.0, down 38.67% from the prior year.
- Other Non-Current Assets grew to $81000.0 in Q1 2026 per TOVX's latest filing, from $46000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $102000.0 in Q4 2023 and bottomed at $23000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $61411.8 across 5 years, with a median of $77000.0 in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 343.48% — and 2025, when it slumped 41.77%.
- Theriva Biologics' Other Non-Current Assets stood at $23000.0 in 2022, then surged by 343.48% to $102000.0 in 2023, then decreased by 26.47% to $75000.0 in 2024, then tumbled by 38.67% to $46000.0 in 2025, then jumped by 76.09% to $81000.0 in 2026.
- Business Quant data shows TOVX's Other Non-Current Assets at $81000.0 in Q1 2026, $46000.0 in Q4 2025, and $46000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 80,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80,000.00 |
| Mar 31, 2026 | 81,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 79,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Sep 30, 2023 | 97,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Mar 31, 2023 | 23,000.00 |
| Dec 31, 2022 | 23,000.00 |
| Sep 30, 2022 | 90,000.00 |
| Jun 30, 2022 | 23,000.00 |
| Mar 31, 2022 | 23,000.00 |
| Dec 31, 2021 | 23,000.00 |
| Sep 30, 2021 | 23,000.00 |